Sanofi India share news, announcements and annual reports

NSE: SANOFIBSE: 500674Pharmaceuticals & BiotechnologySmall Cap

Sanofi India Limited · Formerly Aventis Pharma · Face value ₹10 · Listed Oct 1984 on BSE, May 2003 on NSE

₹3,204.10₹14.60 (0.46%)BSE ₹3,204.40

Share price at the NSE close on 30 Oct 2026. Previous close ₹3,189.50.

30 Oct: open ₹3,265.00, high ₹3,422.60, low ₹3,175.10

52-week range of traded prices to 30 Oct 2026

₹2,758.20Low, 23 Oct 2026₹4,834.00High, 30 Oct 2025

Market cap: ₹7,379 Cr614th largest listed
P/E: 20.24
P/B: 8.93
Dividend yield: 3.84%
ROE: 45.3%
ROCE: 57.3%
Debt to equity: 0.00
Volume, NSE: 2,04,44220.0% delivered

Sanofi India board and management

75 filed, newest first. Page 2 of 2.

Dec 2017
- 15 Dec · Management
  Change in Director(s) of the company.
Feb 2017
- 27 Feb · Management
  Pursuant to the provisions of Section 139 of the Companies Act 2013, as amended, and rules framed thereunder, the Company is required to rotate its Statutory Auditors in the next Annual General Meeting (AGM) of the Company. M/s. SRBC & Co. LLP are the present Statutory Auditors of the Company. The Board of Directors of the Company at its Meeting held on February 27, 2017, subject to the approval of the shareholders at the 61st AGM, recommended the appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP as Statutory Auditors for a period of five years, from the conclusion of the Sixty-first AGM, until the conclusion of the Sixty-sixth AGM of the Company.
- 27 Feb · Management
  Board of Directors of the Company at its Meeting held to February 27, 2017 took note of resignation of Mr. J. Silvestre and Mr. P. Chocat as Non-Executive Directors of Company from the close of the business hours on February 26, 2017. Consequently, Mr. N. Rajaram and Mr. A. Sood ceased to be Alternate Directors of Mr. J. Silvestre and Mr. P. Chocat respectively. Mr. N. Rajaram and Mr. A. Sood will however continue as Whole Time Directors of the Company. The Board also approved the appointment of Mr. Cyril Grandchamp-Desraux and Mr. Thomas Rouckout as Additional Directors on the Board of the Company w.e.f February 27, 2017. The said Directors will hold the office up to the next Annual General Meeting of the Company. Mr. Cyril Grandchamp-Desraux and Mr. Thomas Rouckout are not related to any Directors of the Company
Nov 2016
- 7 Nov · Management
  Change in Company Secretary, Compliance Officer and Key Managerial Personnel.
Jun 2016
- 2 Jun · Management
  At the meeting of the Board of Directors held on June 02, 2016 Mr. Aditya Narayan has been elected as the Chairman of the Board of Directors to hold such office as long as he is an Independent Director of the Company.It will be recalled that Mr. Aditya Narayan had been elected by the shareholders of the Company at the Annual General Meeting held on April 29, 2016 as an Independent Director for an initial term of five years from April 30, 2016.
Oct 2015
- 20 Oct · Management
  Board of Directors has, its meeting held on October 20, 2015, appointed the following Alternate Directors with effect from October 21, 2015:a) Mr. N. Rajaram (presently designated as Country Head and General Manager - Pharmaceutical Operations) as Alternate to Mr. J. Silvestreb) Mr. Lionel Guerin (presently designated as Chief Financial Officer) as Alternate to Mr. F.Briensc) Mr. A. Sood (presently designated as Senior Director- Industrial Affairs) as Alternate to Mr. P. ChocatAs all three of them are employees of the Company, they become Wholetime Directors.
- 20 Oct · Management
  Board of Directors has, at its meeting held on October 20, 2015, re-appointed Dr. Shailesh Ayyangar as Managing Director of the Company for a further term of five years from October 25, 2015 subject to approval of the shareholders in general meeting.Dr. Ayyangar had been designated Managing Director of the Company on October 25, 2005. He was subsequently re-appointed as Managing Director for a term of five years from October 25, 2010.
Jul 2015
- 27 Jul · Management
  Ms. Virginie Simone Jeanine Verrechia (Ms. Virginie Boucinha) who has been the Chief Financial Officer (CFO) from July 01, 2012 and Director of the Company from July 25, 2012 has stepped down as the CFO as she has taken up a senior position with the Sanofi Group in France.
- 27 Jul · Management
  Changes in the Board of Directors.
Jan 2015
- 30 Jan · Management
  Mr. A. Ortoli, who was Senior Vice President, Intercontinental, Global Operations of Sanofi SA, France (the Company's ultimate holding company) has resigned as a Director of the Company with effect from January 21, 2015 following his retirement from the Sanofi Group.
Oct 2013
- 31 Oct · Management
  Board of Directors of the Company has at its Meeting held on October 30, 2013 appointed Mr. Rangaswamy R. Iyer as an Independent Director of the Company in the casual vacancy caused by the resignation of Mr. J. M. Gandhi (who had resigned as a Director of the Company with effect from July 01, 2013).
Jul 2013
- 3 Jul · Management
  Mr.J. M. Gandhi, Independent Director of the Company, who is a Chartered Accountant has informed the Company that he would be retiring shortly as partner of M/s N. M. Raiji & Co. and after the said retirement he would be joining another reputed Chartered Accountants' firm as a partner. He has further informed that as per the internal code of conduct of the new firm he is not allowed to take up directorship of any company to avoid any possible conflict of interest. Mr. Gandhi has therefore, resigned as a Director of the Company with effect from July 01, 2013.
May 2013
- 8 May · Management
  Board of Directors of the Company at its meeting held on April 30, 2013, has appointed Ms. Joanna Potts as Alternate to Mr. A. Ortoli with effect from May 01, 2013
Feb 2013
- 14 Feb · Management
  Mr. S. Umesh has resigned as Alternate Director/Wholetime Director of the Company with effect from February 01, 2013 as he is taking up a position in the Sanofi Group in France.
Jun 2012
- 27 Jun · Management
  Mr. M. Dargentolle has resigned as Chief Financial Officer and Wholetime Director of the Company with effect from the close of business hours from June 30, 2012 as he is taking up a position in the R & D Division of the Sanofi Group in France.
May 2012
- 10 May · Management
  At its Meeting held on May 3, 2012, the Board of Directors has appointed Mr. S. Umesh as Alternate to Mr. Ortoli with effect from May 4, 2012.
Aug 2011
- 30 Aug · Management
  Mr. O. Charmeil and Mr. F. X. Duhalde have resigned as Directors of the Company with effect from August 23, 2011. The Board of Directors has appointed Mr. A. Ortoli (Senior Vice President - Intercontinental of the Sanofi Group) and Mr. F. Briens (Vice President - Finance, Intercontinental of the Sanofi Group) as Directors of the Company in the casual vacancies caused by the resignations of Mr. Charmeil and Mr. Duhalde, respectively.
Apr 2011
- 11 Apr · Management
  Mr. S. C. Ghoge has resigned as Alternate Director to Mr. F.X. Duhalde and Wholetime Director with effect from the close of business hours on March 31, 2011 as he has taken premature retirement from the services of the Company.
Nov 2010
- 8 Nov · Management
  At its Meeting held on October 25, 2010, the Board of Directors has appointed Mr. M. G. Rao and Mr. S.C Ghoge as Alternates to Mr. J. M. Georges and Mr. F. X. Duhalde.
Sep 2010
- 9 Sep · Management
  Following changes have taken place in the Board of Directors of the Company : (1) Mr. M. Dargentolle, Chief Financial Officer of the Company who was Alternate Director to Mr. O. Charmeil has been appointed a Director of the Company with effect from July 19, 2010; (2) Mr. J. M. Georges, Director, Industrial Pharma Intercontinental of the sanofi-aventis Group and Mr. F. X. Duhalde, Director - Finance & Administration of the sanofi-aventis Group, have been appointed as Additional Directors of the Company with effect from July 29, 2010.
Aug 2010
- 31 Aug · Management
  Notice sent to Shareholders regarding re-appointment of Dr. S. Ayyangar as Managing Director of the Company.
Aug 2009
- 25 Aug · Management
  Mr. Christophe Germain, Chief Financial Officer and Wholetime Director of the Company has been appointed as the Chief Financial Officer of the sanofi-aventis affiliate in South Korea. Mr. Germain has accordingly resigned as Chief Financial Officer and Director of the Company with effect from the close of business hours on 31st July 2009
Apr 2007
- 18 Apr · Management
  The Board of Directors has, at its Meeting held on 16th April, 2007, appointed Mr. S.C. Ghoge as Alternate Director to Mr. Eric Le-Bris. Mr. Ghoge being an employee of the Company, has been appointed a Wholetime Director
Mar 2007
- 23 Mar · Management
  Mr. F. Delille, Director has resigned as Director on 7th March, 2007. At its Meeting held on 16th March, 2007, the Board has appointed Mr. Eric Le-Bris as an Additional Director
- 6 Mar · Management
  Dr. S. Bhattacharya, Wholetime Director and Alternate Director of the Company has resigned as Director and as an employee of the Company with effect from the close of business hours on 23rd February 2007 as he has taken up an overseas appointment outside the Company

Sanofi India board and management

Dec 2017

Feb 2017

Nov 2016

Jun 2016

Oct 2015

Jul 2015

Jan 2015

Oct 2013

Jul 2013

May 2013

Feb 2013

Jun 2012

May 2012

Aug 2011

Apr 2011

Nov 2010

Sep 2010

Aug 2010

Aug 2009

Apr 2007

Mar 2007